On October 7, ARK Genomic Revolution ETF fell 8.03% in regular trading, trading at $52.21 per share, with turnover of $589 million. The decline was driven by selling pressure in medical heavyweight holdings following ARK Invest's recent portfolio adjustments.

According to fund flow data, ARK Invest executed a series of rebalancing trades across multiple ETFs. ARKK and ARKG simultaneously purchased Intellia Therapeutics while reducing positions in other holdings. Market participants noted that ARKK and ARKG carry heavy exposure to healthcare stocks, and the adjustment-triggered selling pressure spread across the genomics and medical sector, directly weighing on the fund's net asset value.

Community discussions also highlighted that the healthcare-heavy positioning of ARKK and ARKG amplified the sector-wide decline. Some investors pointed to the rebalancing-driven selloff as the primary reason for the intraday drop, while suggesting that the full updated holdings disclosure would not be visible until later in the week.

ARKG is an actively managed ETF that seeks long-term growth of capital by investing primarily in domestic and foreign equity securities across healthcare, information technology, materials, energy, and consumer discretionary sectors relevant to the genomics revolution theme.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)